| Trial ID: | L0095 |
| Source ID: | NCT04882813
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Relative hazard of the composite of end-stage renal disease or all-cause mortality, Claims-based algorithm: see attached protocol for full definition, To study completion or censoring, up to 32 months | Secondary: Relative hazard of end-stage renal disease, Claims-based algorithm: see attached protocol for full definition, To study completion or censoring event, up to 32 months|Relative hazard of all-cause mortality, Claims-based algorithm: see attached protocol for full definition, To study completion or censoring event, up to 32 months
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
87727
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2020-12-13
|
| Completion Date: |
2021-06-11
|
| Results First Posted: |
|
| Last Update Posted: |
2023-07-28
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04882813
|
